Brigitte Simon
Research Subjects
Brigitte Simon has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Corcos
Inserm UMR1078, 22 avenue Camille Desmoulins, Brest 29200, France; Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé, 22 avenue Camille Desmoulins, Brest 29200, France; Établissement Français du Sang (EFS) Bretagne, 46 rue Félix Le Dantec, Brest 29200, France; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, 5 avenue Foch, Brest 29200, France
2 shared publications - Beatrice Eymin
University Grenoble Alpes, INSERM U1209, CNRS UMR5309, Team RNA Splicing, Cell Signaling and Response to Therapies, Institute For Advanced Biosciences Grenoble France
1 shared publication - Catherine Le Jossic-Corcos
Inserm U1078, Univ Brest, EFS, F-29200 Brest, France
1 shared publication - Danièle Gillet
INSERM U613-ECLA and IFR148-ScInBioS, Université Européenne de Bretagne, Université de Bretagne Occidentale, Faculté de médecine, 22 avenue Camille Desmoulins, 29200 Brest, France
1 shared publication - Julie Follet
INSERM U613-ECLA and IFR148-ScInBioS, Université Européenne de Bretagne, Université de Bretagne Occidentale, Faculté de médecine, 22 avenue Camille Desmoulins, 29200 Brest, France
1 shared publication - Lionel Rémy
INSERM U865, Faculté de Médecine RTH Laennec, 7 rue Guillaume Paradin, 69372 Lyon cedex 08, France
1 shared publication
Latest Publications
- Open Access
- 15 January 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 9
A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies
Alternative pre-mRNA splicing (AS) widely expands proteome diversity through the combinatorial assembly of exons. The analysis of AS on a large scale, by using splice-sensitive microarrays, is a highly efficient method to detect the majority of known and predicted alternative transcripts for a given gene. The response to targeted anticancer therapies cannot easily be anticipated without prior knowledge of the expression, by the tumor, of target proteins or genes. To analyze, in depth, transcript structure and levels for genes involved in these responses, including AKT1-3, HER1-4, HIF1A, PIK3CA, PIK3R1-2, VEGFA-D and PIR, we engineered a dedicated gene chip with coverage of an average 185 probes per gene and, especially, exon-exon junction probes. As a proof of concept, we demonstrated the ability of such a chip to detect the effects of over-expressed SRSF2 RNA binding protein on the structure and abundance of mRNA products in H538 lung cancer cells conditionally over-expressing SRSF2. Major splicing changes were observed, including in HER1/EGFR pre-mRNA, which were also seen in human lung cancer samples over-expressing the SRSF2 protein. In addition, we showed that variations in HER1/EGFR pre-mRNA splicing triggered by SRSF2 overexpression in H358 cells resulted in a drop in HER1/EGFR protein level, which correlated with increased sensitivity to gefitinib, an EGFR tyrosine kinase inhibitor. We propose, therefore, that this novel tool could be especially relevant for clinical applications, with the aim to predict the response before treatment.
- 15 January 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 9
Open AccessA dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies
Alternative pre-mRNA splicing (AS) widely expands proteome diversity through the combinatorial assembly of exons. The analysis of AS on a large scale, by using splice-sensitive microarrays, is a highly efficient method to detect the majority of known and predicted alternative transcripts for a given gene. The response to targeted anticancer therapies cannot easily be anticipated without prior knowledge of the expression, by the tumor, of target proteins or genes. To analyze, in depth, transcript structure and levels for genes involved in these responses, including AKT1-3, HER1-4, HIF1A, PIK3CA, PIK3R1-2, VEGFA-D and PIR, we engineered a dedicated gene chip with coverage of an average 185 probes per gene and, especially, exon-exon junction probes. As a proof of concept, we demonstrated the ability of such a chip to detect the effects of over-expressed SRSF2 RNA binding protein on the structure and abundance of mRNA products in H538 lung cancer cells conditionally over-expressing SRSF2. Major splicing changes were observed, including in HER1/EGFR pre-mRNA, which were also seen in human lung cancer samples over-expressing the SRSF2 protein. In addition, we showed that variations in HER1/EGFR pre-mRNA splicing triggered by SRSF2 overexpression in H358 cells resulted in a drop in HER1/EGFR protein level, which correlated with increased sensitivity to gefitinib, an EGFR tyrosine kinase inhibitor. We propose, therefore, that this novel tool could be especially relevant for clinical applications, with the aim to predict the response before treatment.
- Open Access
- 22 November 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 491
Adaptation to statins restricts human tumour growth in Nude mice
Statins have long been used as anti-hypercholesterolemia drugs, but numerous lines of evidence suggest that they may also bear anti-tumour potential. We have recently demonstrated that it was possible to isolate cancer cells adapted to growth in the continuous presence of lovastatin. These cells grew more slowly than the statin-sensitive cells of origin. In the present study, we compared the ability of both statin-sensitive and statin-resistant cells to give rise to tumours in Nude mice.
- 22 November 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 491
Open AccessAdaptation to statins restricts human tumour growth in Nude mice
Statins have long been used as anti-hypercholesterolemia drugs, but numerous lines of evidence suggest that they may also bear anti-tumour potential. We have recently demonstrated that it was possible to isolate cancer cells adapted to growth in the continuous presence of lovastatin. These cells grew more slowly than the statin-sensitive cells of origin. In the present study, we compared the ability of both statin-sensitive and statin-resistant cells to give rise to tumours in Nude mice.